sym_recorded
Description

Title: Current Status on Osteonecrosis of the Jaw Translational Research

Moderators: J.I. Aguirre, DVM, PhD and Donald B. Kimmel, DDS, PhD
Speakers:
Dr. Indraneel Bhattacharyya
Dr. Ichiro Nishimura
Dr. Junro Yamashita
Dr. Sotirios Tetradis

Schedule:
Keynote Speech: (6 min)
Four Data talks at 12min +4 min Q&A per speaker.
Panel discussion (with all four speakers), plus Moderators (Aguirre, Kimmel), Dr. Tara Aghaloo (UCLA; Organizer), and Closing remarks by Dr. Jason Wan (NIDCR): 20 min

Symposium Mission Statement
ONJ is “here to stay.” ONJ, particularly that of the spontaneous variety, is regarded as a common (1-2%), yet unpredictable, side effect in oncology patients taking high doses of powerful antiresorptives for control of bone metastasis and hypercalcemia. It is not reasonable to conduct ONJ clinical trials of a significant size, because the availability and severity of clinical cases suitable for study cannot be predicted. An appropriate and complementary set of ONJ animal models may not only facilitate a better understanding of ONJ pathophysiology, but also provide a means to test novel pharmacologic concepts for preventing/treating ONJ. The overall intent is to provide more tools that will improve the ability of the medical and dental communities to cope with ONJ.
In this symposium we propose to assemble a group of experienced ONJ investigators who will discuss: 1) an overview of the clinical and histopathologic features of ONJ; 2) the gross anatomic/histopathologic conditions and findings that should be present in relevant animal models; and 3) the status of several preclinical ONJ models and their more recent data, including the role of the oral mucosa; the effects of antiresorptives and VEGF-antagonists on wound healing and the role of periodontal/periapical infection. After the talks, a panel will be convened to answer pre-submitted and ad hoc questions from meeting attendees.

Partially supported by BioVinc

Talk contents:
Human ONJ
Dr. Indraneel Bhattacharyya: Is an experienced oral pathologist that is highly qualified and experienced to provide us with an overview about the clinical and histopathological features of ONJ. During his talk, he will also provide us with the expected requirements and findings to be observed for animal model to be accepted as relevant in the preclinical setting.

Status of Preclinical models and their more recent data
Dr. Ichiro Nishimura: will talk about the role of the oral mucosa and immunity in the pathophysiology of ONJ. He will provide the therapeutic prophylaxis of ONJ based on the bisphosphonate-bone association through competitive equilibrium concept, which is currently undergoing a pre-clinical study.
Dr. Junro Yamashita: will talk about the effects of antiresorptives and VEGF-antagonists on wound healing and ONJ. He will discuss on the use of bone anabolic stimulation such as parathyroid hormone (PTH) and its derivatives for a potential therapeutic approach.
Dr. Sotirios Tetradis: will talk about the role of periodontal disease and periapical infection in the development of ONJ. They will provide the critical validation of rodent models of ONJ with bisphosphonates and Denosumab, a humanized antibody against anti-RANKL ligand, and demonstrate the strengths and limitations of animal models for the development of human disease therapies.

Learning Objectives:

  • Learn about the clinical and histopathologic features of ONJ.
  • Learn about the gross anatomic/histopathologic features and findings that should be present in relevant animal models of ONJ.
  • Learn about the status of several preclinical ONJ models and their more recent data, including the role of the oral mucosa; the effects of antiresorptives and VEGF-antagonists on wound healing and the role of periodontal/periapical infection.
Presentations
Sponsoring Group/Network